scholarly journals The effect of the health poverty alleviation project on the burden of congenital heart disease for Kizilsu Kirghiz Autonomous Prefecture, China

2021 ◽  
Author(s):  
Cheng Zhang ◽  
Chunyu Li ◽  
Aizezi Gulisitan ◽  
Ainiwa Milinuer ◽  
Zhenhai Zhang ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Poverty Alleviation ◽  
Congenital Heart ◽  
Financial Burden ◽  
Poor People ◽  
Disability Adjusted Life Years ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Epidemiology Data

Abstract Background: The implement of the health poverty alleviation project is a very important initiative for reducing poverty. Although previous studies have analyzed the effect of impoverishment, few papers compared the differences of the economy and the morbidity after the implement of the health poverty alleviation project in China. Methods: To analyze the effect of the health poverty alleviation project on the burden of congenital heart disease, we collected the hospitalization expenses and epidemiology data of congenital heart disease in Kizilsu Kirghiz Autonomous Prefecture from 2016 to 2018, in which the health poverty alleviation project was implemented. SPSS 23.0 and Disability Adjusted Life Years were applied to analyze the burden of the disease. Results: Our study found that the prevalence rate of congenital heart disease was increasing year by year. In total, 4719 poor people enjoyed the welfare of health poverty alleviation in the People's Hospital of Kezhou. The out-of-pocket ratio was only 2.25%. After the health poverty alleviation project, the loss of Disability Adjusted Life Years was smaller and smaller. 24 sessions have been carried out to operate 208 patients with congenital heart disease, all of which have been successful. Conclusions: This study found that the health poverty alleviation project not only bringed healthy life expectancy to poor families, but also greatly reduces their financial burden.

scholarly journals Disability-adjusted life years lost due to ischemic heart disease in mainland Portugal, 2013

2017 ◽  
Vol 36 (4) ◽  
pp. 273-281
Author(s):  
Ana Henriques ◽  
Carla Araújo ◽  
Marta Viana ◽  
Olga Laszczynska ◽  
Marta Pereira ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Disability Adjusted Life Years ◽  
Mainland Portugal ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Life Years Lost

scholarly journals Disability-adjusted life years lost due to ischemic heart disease in mainland Portugal, 2013

2017 ◽  
Vol 36 (4) ◽  
pp. 273-281 ◽  
Author(s):  
Ana Henriques ◽  
Carla Araújo ◽  
Marta Viana ◽  
Olga Laszczynska ◽  
Marta Pereira ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
Disability Adjusted Life Years ◽  
Mainland Portugal ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Life Years Lost

scholarly journals Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017

Hypertension ◽  
2021 ◽  
Vol 77 (4) ◽  
pp. 1223-1233
Author(s):  
Haijiang Dai ◽  
Nicola Luigi Bragazzi ◽  
Arwa Younis ◽  
Wen Zhong ◽  
Xinyao Liu ◽  
...  
Keyword(s):  
Heart Disease ◽  
Prevalence Rate ◽  
Public Awareness ◽  
Hypertensive Heart Disease ◽  
Disability Adjusted Life Years ◽  
Uncertainty Interval ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Global Age ◽  
Disability Adjusted Life Year

Hypertensive heart disease (HHD) is a major cause of global morbidity and mortality. Understanding its current burden among various countries and populations is crucial for formulating effective strategies for preventing and managing HHD. This study aimed to use the estimates from the Global Burden of Disease Study 2017 to describe the prevalence, mortality, and disability-adjusted life years for HHD for 195 countries and territories from 1990 to 2017. Worldwide, the age-standardized prevalence rate of HHD in 2017 was 217.9 (95% uncertainty interval [UI], 184.1–254.1) per 100 000 people, an increase of 7.4% (95% UI, 5.0–9.7) from 1990. The global age-standardized mortality and disability-adjusted life year rates of HHD were 12.3 (95% UI, 9.0–13.2) and 209.4 (95% UI, 160.5–226.3) per 100 000 people, a decrease of −19.3% (95% UI, −29.7 to −8.1) and −24.0% (95% UI, −31.0 to −13.7) from 1990, respectively. The global age-standardized prevalence rate of HHD was higher in females and increased with age. Between 1990 and 2017, Bolivia (51.3% [95% UI, 29.6–84.5]) and Maldives (32.3% [95% UI, 22.9–43.8]) showed the greatest increases in age-standardized prevalence rates. Generally, a negative association was found between the age-standardized disability-adjusted life year rates and Sociodemographic index at the regional and national levels. Our results suggest that HHD is a major public health challenge worldwide with an increasing prevalence rate over the past decades. Efforts to improve public awareness and management of high blood pressure and HHD, especially for vulnerable populations, were necessary.

Abstract 1779: The Negative Impact of Diagnostic Testing Performed Prior to Adult Congenital Heart Disease Referral - Financial Burden and Cost to the Patient

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Curt J Daniels ◽  
Rakhi Gupta ◽  
Elizabeth A Sparks ◽  
Stephen C Cook ◽  
Jenne Hickey ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Financial Burden ◽  
Adult Congenital Heart Disease ◽  
Diagnostic Testing ◽  
Specialized Training ◽  
Repeat Testing ◽  
Adult Congenital ◽  
Unnecessary Testing

Adult congenital heart disease (ACHD) patients (pts) are an underserved, complex, rapidly expanding population and, despite surpassing the volume of pediatric CHD pts, neither IM or pediatric cardiology fellowship fully prepares physicians to care for this group. The diagnostic studies recommended, technical skills required, and unique data interpretation requires specialized training in both disciplines. Therefore, we sought to determine whether pts referred to our ACHD program underwent appropriate and complete testing prior to referral and evaluated the financial impact of unnecessary and repeat testing. Methods: We reviewed diagnostic testing before and after referral to the ACHD program for consecutive new pts (>18 yo). All cardiovascular testing prior to referral and subsequent testing were recorded. Unnecessary testing was defined as those performed outside of guidelines or inappropriate for their CHD. Incomplete testing was defined as that which required repeating. Financial cost of unnecessary and repeat testing was estimated based on usual insurance billing practice. Results: From 2/06 to 4/07, 200 new pts were referred to the ACHD program, mean age 33.2 ± 12.7 yrs (range 18.1–72.9 yrs). Common diagnoses included ASD (17%), TOF (14%), bicuspid aortic valve (11%) and COA (10%) with 81% classified as moderate or complex CHD. Unnecessary testing consisted of 35 stress studies (25 nuclear and 10 echo), 5 TEEs, and 14 cardiac caths. Repeat studies for incomplete testing were necessary in 65/81 TTEs (80%), 9/39 TEEs (23%), 0/5 cardiac CTs, 8/12 CMRs (67%) and 16/31 caths (51%). Overall,105/200 pts (52%) endured unnecessary or repeat testing carrying a conservative financial burden of $456,980; 916 patient hours: and 114 patient work days lost. Conclusions: Diagnostic testing in ACHD requires specialized training from technician to physician. Repeat testing was necessary in 58% of studies, and 52% of the pts were affected by unnecessary or repeat testing. Therefore, ACHD pts frequently endure unnecessary and repeat testing which carries a financial burden to the patient and health care system and medical risk to the patient. Adults with moderate and complex CHD should be referred to appropriately trained ACHD providers prior to diagnostic testing.

scholarly journals Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention

2021 ◽  
Vol 9 ◽  
Author(s):  
Zhiyong Li ◽  
Longfei Lin ◽  
Hongwei Wu ◽  
Lei Yan ◽  
Huanhuan Wang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Heart Disease ◽  
Global Burden ◽  
Disability Adjusted Life Years ◽  
Disability Adjusted Life ◽  
Life Years ◽  
The World ◽  
Disease Study ◽  
Cvd Mortality

Background: Cardiovascular disease is the leading cause of death worldwide and a major barrier to sustainable human development. The objective of this study was to evaluate the global, sex, age, region, and country-related cardiovascular disease (CVD) burden, as well as the trends, risk factors, and implications for the prevention of CVD.Methods: Detailed information from 1990 to 2017, including global, regional, and national rates of CVD, and 11 categories of mortality and disability-adjusted life years (DALYs) were collected from the Global Burden of Disease Study 2017. The time-dependent change in the trends of CVD burdens was evaluated by annual percentage change.Results: More than 17 million people died from CVD in 2017, which was approximately two times as many as cancer, and increased nearly 50% compared with 1990. Ischemic heart disease and stroke accounted for 85% of the total age-standardized death rate (ASDR) of CVD. The ASDR and age-standardized DALYs rate (ASYR) of CVD were 1.5 times greater in men compared with women. People over the age of 50 were especially at risk for developing CVD, with the number of cases and deaths in this age group accounting for more than 90% of all age groups. CVD mortality was related to regional economic development and the social demographic index. In regions with a high economic income or socio-demographic index, there was a greater decline in the ASDR of CVD. The ASDR of CVD in high SDI regions decreased more than 50% from 1990 to 2017. Tobacco use, diets low in whole grains, diets high in sodium, and high systolic blood pressure were the important risk factors related to CVD mortality.Conclusions: CVD remains a major cause of death and chronic disability in all regions of the world. Ischemic heart disease and stroke account for the majority of deaths related to CVD. Although the mortality rate for CVD has declined in recent years from a global perspective, the results of CVD data in 2017 suggest that the mortality and DALYs of CVD varied in different ages, sexes, and countries/regions around the world. Therefore, it is necessary to elucidate the specific characteristics of global CVD burden and establish more effective and targeted prevention strategies.

scholarly journals Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Eva Fernlund ◽  
Martin Eriksson ◽  
Jonas Söderholm ◽  
Jan Sunnegårdh ◽  
Estelle Naumburg
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Congenital Heart ◽  
Heart Surgery ◽  
Cost Savings ◽  
Life Years ◽  
Increased Risk ◽  
Syncytial Virus ◽  
One Year

Abstract Background Infants with congenital heart disease (CHD) have an increased risk of morbidity and mortality during a respiratory syncytial virus (RSV) infection. The aim of this study was to estimate the cost-effectiveness of palivizumab as RSV-prophylaxis among infants with CHD, including the effect of delayed heart surgery and asthma. Methods A simulation model with data from the literature and health care authorities including costs and utilities was developed to estimate costs and health effects over a lifetime for a cohort of CHD infants receiving palivizumab compared to no RSV-prophylaxis. Results The prophylaxis treatment incurred a cost of 3664 EUR per treated infant. However, due to cost-savings from primarily avoiding hospitalizations (5145 EUR/treated infant) and avoiding heart complications due to delayed heart surgery (2082 EUR/treated infant), the RSV-prophylaxis treatment resulted in a total cost-saving of 3833 EUR per treated infant. At the same time, the prophylaxis-treated cohort accumulated more life-years and higher quality of life than the non-prophylaxis cohort. Conclusion This study confirms that RSV-prophylaxis in severe CHD infants less than one year of age is cost beneficial. Avoiding delayed heart surgeries is an important benefit of prophylaxis and should be taken into consideration.

Sign in / Sign up

Export Citation Format

Share Document